Indeed, there is preclinical and clinical data from T cell-inflamed tumors14 showing that in situ vaccination with Flt3L, RT, and TLR3 agonist facilitates cross-priming of tumor-specific T cells, and synergizes with PD-1 blockade. Here, TLR3 is linked to neoplasm.